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  The pharmacokinetics of orally administered pefloxacin 
w ere s tudied to eval uate the bio-enhancing effect of the 
herbal  bio-enhancer,  trikatu,  in  mountain  Gaddi  goats    
( n =  6 ) .  T h e f i n d i n g s  o f t h e s t u dy  r e v ea l ed  a  d ec r ea s e d  
plasma  concentration  (p  >  0.05)  of  pefloxacin  following 
trikatu  administration  during  the  absorption  phase  (10, 
15, 20 min post pefloxacin administration). In contrast, the 
plasma  concentrations  of  pefloxacin  were  significantly 
higher at 4, 6, 8 and 12 h (during the elimination phase) of 
the  pefloxacin  administration.  The  findings  of  the  inve-
stigation  revealed  higher  values  for  the  area  under  the 
curve, the area under the first moment of the plasma drug 
concentration time curve, the mean residential time, the 
total  duration  of  pharmacological  action  and  bioavaila-
bility. Trikatu treatment, however, significantly reduced the 
elimination half life (t1/2β) and zero time intercept of the 
elimination  phase.  The  apparent  volume  of  distribution 
based on the total area under the plasma drug concentration 
curve [(Vd(area)] and the apparent volume of distribution 
based on the zero time plasma concentration intercept of 
the elimination phase [Vd(B)] were significantly higher in 
trikatu treated animals indicating a better penetration of 
the drug. Based on the MIC of 0.8 µg/ml of pefloxacin, a 
priming dose of 6.0 mg/kg and a maintenance dose of 2.21 
mg/kg is required to be administered at 8 h intervals. For 
practical  purposes  in  goats  this  would  mean  a  priming 
dose of 6 mg/kg and a maintenance dose of 2 mg/kg given 
by the oral route, to be repeated at 8 h intervals. 
Keywords: goats, oral administration, pefloxacin, pharmaco-
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Introduction 
  Fluoroquinolones are now becoming the antibacterials of 
choice in veterinary therapeutics. The fluoroquinolones 
have also become popular as there are minimal chances of 
bacterial resistance with these agents. The pharmaco-
kinetics of pefloxacin are clearly described in various 
species [1,8,10,15]. Inspection of the pharmacokinetic 
behavior in various animal species reveals that the drug is 
poorly absorbed in goats following its oral administration. 
One practical approach to enhance the bioavailability is by 
using herbal bio-enhancers with the antibacterial agents. 
Piper longum pretreatment has been successfully employed 
as a bio-enhancer with orally administered oxytetracycline 
in WLH poultry birds [7]. In the present study, the effect of 
the herbal bio-enhancer, trikatu (equal parts of Piper 
longum,  Piper nigrum and Zingiber officinale) on the 
pharmacokinetic behaviour of pefloxacin in mountain 
Gaddi goats is presented.
Materials and Methods
  The study was conducted on six adult healthy mountain 
Gaddi goats weighing 18-22 kg. The same animals were 
used for both treatments after a wash out period of 15 days. 
The goats were kept under close observation before 
beginning the experiments to enable them to acclimatize to 
the new environment. In the first treatment pefloxacin 
(Pelwin; Wokhardt, India) was given at the dose rate of 20 
mg/kg body weight whereas in second treatment animals 
were orally administered trikatu (piperine contents of 
trikatu 2.02% (w/w)) at a dose rate of 2 g/kg for 14 days and 
on day 15, pefloxacin was administered at the dose rate of 
20 mg/kg. 5 ml blood samples were collected from each 
animal in heparinized tubes at 10, 15, 20, 30, 45, 60, 120, 
240, 360, 480 and 720 min post drug administration and 
were centrifuged at 3,000 rpm for 10 min for plasma 26    Madhukar S. Dama et al.
Table 1. Comparative pharmacokinetic profile of pefloxacin 
administered orally (20 mg/kg) in control and trikatu treated 
goats (mean ± SE)
Parameter
# Unit Control Trikatu treated
  Ka
  A
  β
  B
  t1/2Ka
  t1/2β
  AUC
  AUMC
  Vd(area)
  Vd(B)
  ClB
  MRT
  td
  F
/h
µg/ml
/h
µg/ml
/h
/h
µg/ml.h
µg/ml.h
2
l/kg
l/kg
l/kg/h
h
h
%
    2.20 ± 0.09
    9.06 ± 0.13
    0.26 ± 0
    8.23 ± 0.1
    0.32 ± 0.01
      2.5 ± 0.12
  27.10 ± 0.38
121.10 ± 4.07
    1.11 ± 0.08
    2.43 ± 0.03
    0.29 ± 0.02
    4.47 ± 0.16
  19.72 ± 0.38
  38.83 ± 1.8
   2.18 ± 0.15
   7.96 ± 0.42
   0.21 ± 0.01**
   7.30 ± 0.19**
   0.32 ± 0.02
   3.30 ±0.19**
 30.85 ±1.39**
164.25± 15.62*
   1.37 ± 0.11*
   2.75 ± 0.08*
   0.29 ± 0.02
   5.27 ± 0.27*
 24.16 ± 1.46*
 44.18 ± 2.90*
#Pharmacokinetic parameters as described by Gibaldi and Perrier [5],
Ka: absorption rate constant, A: zero time plasma drug concentration
intercept of regression line of absorption phase, β: overall elimination
rate constant, B: zero time intercept of the regression line of the 
elimination phase, t1/2Ka: absorption half life, t1/2β: elimination half 
life, AUC: area under the curve, AUMC: area under the first moment
of the plasma drug concentration time curve, MRT: mean residential 
time, td: total duration of pharmacological action, ClB: total body 
clearance; Vd(area): volume of distribution based on the total area under 
the plasma drug concentration time curve; Vd(B): volume of 
distribution based on the zero time plasma drug concentration 
intercept of the elimination phase. *p ≤ 0.05, **p ≤ 0.01.
Fig. 1. Comparative semilogarithmic plot of plasma concen-
tration - time profile of pefloxacin in control and trikatu treated
goats following oral administration (20 mg/kg).
separation. The plasma samples were stored at 򰠏20
oC for 
microbial assay. The assay was completed within 1 week.
  The concentration of microbiologically active pefloxacin 
(parent & metabolites) in plasma were determined by the 
agar plate diffusion method [4] using E. coli (strain 
MTCC-443) as the test organism with the modification that 
large petri plates were used instead of large glass plates and 
only three punches were made for the microbial assay. 
  The plasma concentration-time profile of pefloxacin for 
each goat was used to determine the pharmacokinetics. 
Different pharmacokinetic parameters were analysed using 
the “method of least square” and the “method of residual 
yields” as described by Gibaldi and Perrier [5]. Estimation 
of the area under the concentration- time curve (AUC) and 
the area under the first moment of the plasma drug concen-
tration time curve (AUMC) were based on the trapezoidal 
rule [5]. The compartmental analysis of plasma concentration 
vs. time was carried out using the mono-exponential 
equation:
Cp
(t) = Be
- βt - Ae
 -Kat
  Where Cp
(t) is the plasma drug concentration at time t, B 
is the zero time intercept of the regression line of the 
elimination phase, A is the zero time plasma drug con-
centration intercept of the regression line of the absorption 
phase, Ka is the absorption rate constant, β is the overall 
elimination rate constant, t is time and e is the natural 
logarithm base. 
The dosage regimen for maintaining MIC of 0.1-0.8 µg/ml 
for most organisms [13] at dosage interval of 4, 6 and 8 h 
was derived as per the method described by Notari [11].
  The difference between the means of the two treatments 
was determined by student's t-test [14] and the data were 
analyzed using GraphPad Instat (GraphPad Software, 
USA).
Results
  The results of the study revealed that the mean plasma 
concentrations of pefloxacin were consistently lower in 
trikatu treated goats up to 2 h. The values were 
significantly lower at 10 min, 15 min and 20 min post drug 
administration (Table 1 and Fig. 1). The values at 20 min 
post drug administration were 3.17 µg/ml in control animals Effect of trikatu on pefloxacin pharmacokinetics    27
Table 2. Dosage regimen of pefloxacin, calculated on the basis of pharmacokinetic values obtained following its oral administration 
(with and without trikatu treatment) in goats at dosage intervals for micro-organisms of different susceptibilities
Microorganism 
susceptibility 
Dosage interval
4 h  6 h 8 h
Control Trikatu treated Control Trikatu treated Control Trikatu treated
0.1*
0.2
0.3
0.4
0.6
0.8
0.31
†‡
(0.11)
0.62
(0.23)
0.93
(0.34)
1.24
(0.45)
1.86
(0.68)
2.49
(0.91)
0.32
(0.12)
0.64
(0.23)
0.96
(0.35)
1.28
(0.47)
1.92
(0.70)
2.56
(0.94)
0.52
(0.19)
1.04
(0.38)
1.57
(0.57)
2.09
(0.77)
3.14
(1.15)
4.18
(1.54)
0.49
(0.18)
0.98
(0.36)
1.47
(0.54)
1.96
(0.72)
2.94
(1.08)
3.92
(1.44)
0.88
(0.32)
1.76
(0.65)
2.64
(0.97)
3.52
(1.29)
5.28
(1.94)
7.04
(2.59)
0.75
(0.27)
1.50
(0.55)
2.25
0.83
3.0
(1.10)
4.5
(1.65)
6.0
(2.21)
 *Values are expressed as µg/ml. 
†Values given are expressed as mg/kg body weight. 
‡Values given are loading doses and the values in paren-
thesis are maintenance doses.
against 2.87 µg/ ml in trikatu treated goats. In contrast, the 
plasma concentrations of pefloxacin were significantly 
higher at 4, 6, 8 and 12 h post pefloxacin administration. 
The plasma levels were 1.28 µg/ml in trikatu treated 
animals at 8 h whereas the plasma levels were 1.07 µg/ml 
in control animals. 
  The values of the pharmacokinetic determinants in the 
control and trikatu treated animals are given in Table 2.
The values of the absorption rate constant (Ka) and zero 
time intercept of the absorption phase (A
1) revealed a non 
significant difference between the two groups.
    The findings of the present study further revealed 
significantly higher values ( 30.85 ± 1.39 µg/ml.h in trikatu 
treated animals against 27.10 µg/ml.h in control animals) 
for the area under curve (AUC), AUMC, the mean residen-
tial time (MRT) and the total duration of pharmacological 
action (td) in the trikatu treated goats. The mean residential 
time was 5.27 ± 0.27 h in trikatu treated animals against 
4.47 ± 0.16 h in control animals. Similarly, the total 
duration of the td was 24.16 ± 1.46 h in trikatu treated 
animals against 19.72 ± 0.38 h in control animals. The 
bioavailability of the drug was also significantly higher (p 
< 0.05) in trikatu treated goats (44.18 ± 2.90% against 
38.33 ± 1.80% in control animals).
  Prior treatment of the goats with trikatu significantly 
reduced the elimination half life (t1/2β) and the zero time 
intercept of the elimination phase (B). The elimination half 
life was 3.30 ± 0.19 /h in trikatu treated against 2.5 ± 0.12 
/h in control animals. The total body clearance (ClB), 
however, did not show any significant difference in the 
trikatu treated goats.
    The indicators of drug distribution in the body i.e. 
apparent volume of distribution [Vd(area)] and volume of 
distribution based on the zero time plasma drug concen-
tration intercept of the elimination phase [Vd(B)] were 
significantly higher in the trikatu treated goats. The values 
of Vd(area) in trikatu treated goats were 1.37 ± 0.11 l/kg 
whereas the values of Vd(area) were 1.11 ± 0.08 l/kg in 
control animals.  
  The oral priming and maintenance doses of pefloxacin 
based on the minimum inhibitory concentration (MIC) of 
0.1, 0.2, 0.3, 0.4 and 0.6 and 0.8 µg/ml for most of the 
organisms of clinical significance in the control and trikatu 
treated goats are given in Table-2. On the basis of the data 
for microorganisms possessing a minimum inhibitory 
concentration of 0.8 µg/ml, the priming dose of 7.0 mg/kg 
and maintenance dose of 2.59 mg/kg should be repeated at 
8 h intervals. However, following trikatu administration 
the oral priming and maintenance doses would be 6.0 and 
2.21 mg/kg, respectively and for practical purposes a 
priming dose of 6.0 mg/kg and maintenance dose of 2.0 
mg/kg would be required to be administered following 
trikatu co-administration.
Discussion
  Pefloxacin has excellent activity against a wide range of 
gram positive and gram negative microorganisms and it is 28    Madhukar S. Dama et al.
being successfully used in the treatment of various human 
and animal diseases. Pefloxacin is partially metabolized in 
the liver to norfloxacin, which is a potent anti microbial 
agent [10]. Due to its favourable pharmacokinetic proper-
ties such as better bioavailability, better volume of distri-
bution and minimal chances of resistance, it is one of the 
favoured anti bacterial agents for treatment of animal 
diseases. The irregular absorption from the gastrointestinal 
tract of goats limits its therapeutic utility. In goats only 
about 42% of the drug administered orally is available to 
the systemic circulation [8]. 
  Trikatu is an ayurvedic preparation containing an equal 
ratio of long pepper (Piper longum), black pepper (Piper 
nigrum) and ginger (Zingiber officinale). Piperine (1-piperoyl 
piperidine), an amide alkaloid, from a different species of 
pepper is mainly responsible for enhancing the bioavailability 
of concurrently administered drugs [3,7,9]. Ginger in the 
preparation, may also aid the absorption of drugs through 
thermogenesis. 
  The observed plasma values of pefloxacin in goats by oral 
route were best described by a one compartment model. 
This model has also been used by previous workers to 
describe the pharmacokinetics of pefloxacin in various 
domestic species [8]. The findings of the present study 
indicated that plasma concentrations of the drug remained 
lower up to 2 h post drug administration with consistently 
significantly lower concentrations up to 20 min. In contrast, 
in our earlier studies in birds [7], higher plasma values of 
oxytetracycline were observed following Piper longum 
treatment during the absorption phase. The findings of the 
present study in goats therefore ruled out the possibility of 
vasodilatation of enteric vessels [2] during absorption. The 
findings of the present study agreed with those of Lala et al. 
[6] who also observed decreased plasma levels of declo-
fenac sodium during the absorption phase in rabbits. 
  The decreased elimination of the drug was adequately 
supported by the higher values of t1/2β in the present study. 
However, the total body clearance (ClB) remained unaffected 
in the trikatu treated goats. Further, higher values of the 
apparent volume of distribution values based on the 
apparent volume of distribution based on the total area 
under the plasma drug concentration time curve [Vd(area)] 
indicated a better penetration of the drug in various body 
tissues. This was supported by the higher value for the 
apparent volume of distribution based on the zero time 
plasma concentration intercept of elimination phase 
[Vd(B)] The higher values of AUC, AUMC, and MRT in the 
piperine treated goats were indicative of enhanced 
systemic availability of pefloxacin following trikatu admi-
nistration.
    The pharmacokinetic profile of pefloxacin following 
trikatu administration revealed an enhancement of bioa-
vailability. The enhanced bioavailability was not due to 
increased absorption but because of decreased elimination 
as evidenced by the higher values of t1/2β. The decreased 
elimination could either be due to suppression of drug 
metabolizing activities [12] or due to decreased renal 
excretion. 
  In the present study td and MRT were also indicative of 
enhanced systemic availability of pefloxacin in trikatu 
treated goats.
  Based on the MIC data, only a marginal reduction in the 
dose (6-15%) was possible following trikatu admini-
stration. Nonetheless, trikatu administration enhanced the 
duration of antimicrobial action by about 22%.
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